Home » Stocks » Oncternal Therapeutics

Oncternal Therapeutics, Inc. (ONCT)

Stock Price: $2.99 USD 0.01 (0.34%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 53.74M
Revenue (ttm) 2.48M
Net Income (ttm) -19.32M
Shares Out 19.92M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $2.99
Previous Close $2.98
Change ($) 0.01
Change (%) 0.34%
Day's Open 3.00
Day's Range 2.92 - 3.04
Day's Volume 66,199
52-Week Range 2.11 - 6.29

More Stats

Market Cap 53.74M
Enterprise Value 37.54M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.92M
Float 9.86M
EPS (basic) -0.8
EPS (diluted) -0.58
FCF / Share -0.93
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 37,212
Short Ratio 0.47
Short % of Float 0.27%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 21.65
PB Ratio 5.40
Revenue 2.48M
Operating Income -19.42M
Net Income -19.32M
Free Cash Flow -15.13M
Net Cash 16.20M
Net Cash / Share 0.90
Gross Margin -311.60%
Operating Margin -782.27%
Profit Margin -778.80%
FCF Margin -609.63%
ROA -58.50%
ROE -284.41%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$10.50*
Low
10.5
Current: $2.99
High
10.5
Target: 10.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2.432.52------8.0756.79
Revenue Growth-3.81%--------85.8%-
Gross Profit2.432.52------8.0756.79
Operating Income-33.11-7.59-30.66-25.93-21.84-30.35-43.60-49.73-35.9015.10
Net Income-34.19-6.58-30.44-17.72-18.70-39.41-42.11-27.08-33.2915.29
Shares Outstanding10.333.592.492.082.011.170.900.900.820.56
Earnings Per Share-3.31-1.83-12.25-8.54-10.29-33.74-46.90-30.10-40.6027.30
Operating Cash Flow-16.75-7.42-23.46-20.78-20.04-28.76-43.97-37.11-33.09-30.53
Capital Expenditures----0.09--0.011.39-0.14-0.05-0.10
Free Cash Flow-16.75-7.42-23.46-20.87-20.04-28.76-42.58-37.25-33.14-30.62
Cash & Equivalents20.0520.6543.9021.8729.2649.3014.7356.0974.4458.63
Total Debt0.19---------
Net Cash / Debt19.8620.6543.9021.8729.2649.3014.7356.0974.4458.63
Assets21.7421.9646.2424.5032.0350.6515.6157.7778.6664.25
Liabilities7.4351.597.984.6130.1732.824.9210.076.7812.52
Book Value14.31-29.6338.2619.891.8617.8310.6847.7071.8751.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Oncternal Therapeutics, Inc.
Country United States
Employees 11
CEO James B. Breitmeyer

Stock Information

Ticker Symbol ONCT
Stock Exchange NASDAQ
Unique Identifier NASDAQ: ONCT

Description

Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.